13F GuideFiling Basics
What is SEC Form 13F? Ultimate Guide to Institutional Equity Filings
Learn how SEC Form 13F filings work, the $100M threshold, 45-day reporting lag, and how to track top hedge fund holdings.
AlphaSMO Research GuideRead Guide
CIK: 0001582844
Total reported value
$143.5M
$143.5M
34 檔
24.3%
At the close of Q1 2025, Acuta Capital Partners, LLC disclosed equity holdings valued at approximately $143.5M, spread across 34 reported holdings.
In Q1 2025, Acuta Capital Partners, LLC displayed an active expansion posture, initiating 34 new positions and adding to 0 existing holdings, outstripping position reductions.
| # | Ticker | Issuer | Asset Subclass | Weight | Weight Change | Shares Change | 4Q Trend |
|---|---|---|---|---|---|---|---|
| 1 | OCUL | Ocular Therapeutix Inc | Stock-Other | 10.37% | +0.07% | +9.78% | |
| 2 | INSM | Insmed Inc | Stock-Healthcare | 9.38% | — | +1.22% | |
| 3 | TRML | Tourmaline Bio Inc | Stock-Other | 7.53% | — | +21.33% | |
| 4 | WHWK | Whitehawk Therapeutics Inc | Stock-Other | 7.04% | +6.59% | +84.41% | |
| 5 | ELVN | Enliven Therapeutics Inc | Stock-Other | 6.05% | — | -0.79% | |
| 6 | TRVI | Trevi Therapeutics Inc | Stock-Other | 5.73% | — | +1.81% | |
| 7 | SLNOEUR | Soleno Therapeutics Inc | Stock-Other | 5.56% | — | — | |
| 8 | ARGX | Argenx Se - Adr | Stock-Healthcare | 4.82% | +0.60% | +1.64% | |
| 9 | ASND | Ascendis Pharma A/S | Stock-Other | 4.22% | — | +1.58% | |
| 10 | PRAX | Praxis Precision Medicines I | Stock-Other | 3.83% | -0.13% | +29.10% | |
| 11 | CDTX | Cidara Therapeutics Inc | Stock-Other | 3.14% | — | +130.77% | |
| 12 | OCS | Oculis Holding AG | Stock-Other | 2.76% | -1.86% | EXIT | |
| 13 | RVMD | Revolution Medicines Inc | Stock-Healthcare | 2.73% | -1.80% | EXIT | |
| 14 | LQDA | Liquidia CORP | Stock-Other | 2.63% | — | +11.45% | |
| 15 | DRUG | Bright Minds Biosciences Inc | Stock-Other | 2.50% | -1.27% | -13.56% | |
| 16 | ✓ | Helix Acquisition CORP Ii | Stock-Other | 2.45% | — | +3.49% | |
| 17 | MRK | Merck & Co. Inc. | Stock-Healthcare | 2.39% | — | — | |
| 18 | SRZN | Surrozen Inc | Stock-Other | 2.30% | -0.44% | — | |
| 19 | EWTX | Edgewise Therapeutics Inc | Stock-Other | 2.18% | — | -2.51% | |
| 20 | MREO | Mereo Biopharma Group Pl-adr | Stock-Other | 2.07% | — | +1.60% | |
| 21 | ✓ | Stock-Other | 1.57% | — | +2.17% | ||
| 22 | JAZZ | Jazz Pharmaceuticals plc | Stock-Healthcare | 1.38% | — | — | |
| 23 | VSTM | Verastem Inc | Stock-Other | 1.23% | — | — | |
| 24 | GILD | Gilead Sciences Inc | Stock-Healthcare | 1.21% | — | +1.62% | |
| 25 | 430 | Terns Pharmaceuticals Inc | Stock-Other | 1.04% | -18.59% | EXIT | |
| 26 | ZYME | Zymeworks Inc | Stock-Other | 0.95% | — | +1.81% | |
| 27 | RARE | Ultragenyx Pharmaceutical In | Stock-Other | 0.89% | — | +1.38% | |
| 28 | ✓ | Verve Therapeutics Inc | Stock-Other | 0.86% | — | +1.58% | |
| 29 | RCKT | Rocket Pharmaceuticals Inc | Stock-Other | 0.64% | — | -38.03% | |
| 30 | RAPP | Rapport Therapeutics Inc | Stock-Other | 0.19% | — | — | |
| 31 | FBRX | Forte Biosciences Inc | Stock-Other | 0.17% | — | +1.82% | |
| 32 | ARTV | Artiva Biotherapeutics Inc | Stock-Other | 0.16% | +1.76% | NEW | |
| 33 | NUVB-WS | Nuvation Bio Inc -cw27 | Stock-Other | 0.02% | — | — | |
| 34 | ✓ | Enliven Therapeutics Inc | Stock-Other | — | — | — |
| # | Ticker | Issuer | Weight Change | Shares Change | Action |
|---|---|---|---|---|---|
| 1 | OCUL | Ocular Therapeutix Inc | — | NEW | New buy |
| 2 | INSM | Insmed Inc | — | NEW | New buy |
| 3 | TRML | Tourmaline Bio Inc | — | NEW | New buy |
| 4 | WHWK | Whitehawk Therapeutics Inc | — | NEW | New buy |
| 5 | ELVN | Enliven Therapeutics Inc | — | NEW | New buy |
| 6 | TRVI | Trevi Therapeutics Inc | — | NEW | New buy |
| 7 | SLNOEUR | Soleno Therapeutics Inc | — | NEW | New buy |
| 8 | ARGX | Argenx Se - Adr | — | NEW | New buy |
| 9 | ASND | Ascendis Pharma A/S | — | NEW | New buy |
| 10 | PRAX | Praxis Precision Medicines I | — | NEW | New buy |
| 11 | CDTX | Cidara Therapeutics Inc | — | NEW | New buy |
| 12 | OCS | Oculis Holding AG | — | NEW | New buy |
| 13 | RVMD | Revolution Medicines Inc | — | NEW | New buy |
| 14 | LQDA | Liquidia CORP | — | NEW | New buy |
| 15 | DRUG | Bright Minds Biosciences Inc | — | NEW | New buy |
| 16 | ✓ | Helix Acquisition CORP Ii | — | NEW | New buy |
| 17 | MRK | Merck & Co. Inc. | — | NEW | New buy |
| 18 | SRZN | Surrozen Inc | — | NEW | New buy |
| 19 | EWTX | Edgewise Therapeutics Inc | — | NEW | New buy |
| 20 | MREO | Mereo Biopharma Group Pl-adr | — | NEW | New buy |
| 21 | ✓ | — | NEW | New buy | |
| 22 | JAZZ | Jazz Pharmaceuticals plc | — | NEW | New buy |
| 23 | VSTM | Verastem Inc | — | NEW | New buy |
| 24 | GILD | Gilead Sciences Inc | — | NEW | New buy |
| 25 | 430 | Terns Pharmaceuticals Inc | — | NEW | New buy |
| 26 | ZYME | Zymeworks Inc | — | NEW | New buy |
| 27 | RARE | Ultragenyx Pharmaceutical In | — | NEW | New buy |
| 28 | ✓ | Verve Therapeutics Inc | — | NEW | New buy |
| 29 | RCKT | Rocket Pharmaceuticals Inc | — | NEW | New buy |
| 30 | RAPP | Rapport Therapeutics Inc | — | NEW | New buy |
| 31 | FBRX | Forte Biosciences Inc | — | NEW | New buy |
| 32 | ARTV | Artiva Biotherapeutics Inc | — | NEW | New buy |
| 33 | NUVB-WS | Nuvation Bio Inc -cw27 | — | NEW | New buy |
| 34 | ✓ | Enliven Therapeutics Inc | — | NEW | New buy |
According to official SEC Form 13F filings, Acuta Capital Partners, LLC reported a total U.S. public equity portfolio value of $143.5M across 34 disclosed positions in Q1 2025.
Expert Analysis & Guides for Tracking Wall Street Smart Money Movements
Learn how SEC Form 13F filings work, the $100M threshold, 45-day reporting lag, and how to track top hedge fund holdings.
In terms of portfolio concentration, the top 5 core holdings (including OCUL, INSM, TRML) accounted for 24.3% of total reported equity market value during Q1 2025.
Top New Position Initiated
OCUL
市值: $8.9M
During Q1 2025, Acuta Capital Partners, LLC's top holdings by market value included OCUL (10.4%)、INSM (9.4%)、TRML (7.5%). The largest single position, OCUL, represented 10.4% of total portfolio value.
In Q1 2025, Acuta Capital Partners, LLC made 34 total portfolio adjustments, initiating 34 new buys, adding to 0 positions, trimming 0 holdings, and fully liquidating 0 stocks.
All holding records on this page are fetched directly from the U.S. Securities and Exchange Commission (SEC) EDGAR system (Form 13F-HR). AlphaSMO parses CUSIP identifiers and formats data into Schema.org-compliant datasets.
Understand SEC Form 4 insider disclosures for corporate officers, directors, and 10% owners to track executive transactions.
Understand Rule 144 restricted stock sale notices to spot planned insider liquidations before market sell pressure arrives.
Explore the 5% beneficial ownership threshold, 13D vs 13G filing differences, and recent SEC accelerated deadline rules.
Best practices for analyzing 13F quarterly changes without getting misled by stock splits, options, or market valuation drift.
Learn how AlphaSMO's flagship signal detects high-conviction stocks where 13F hedge funds and corporate insiders buy at the same time.